Delayed
Nasdaq
11:21:16 2024-05-17 am EDT
|
5-day change
|
1st Jan Change
|
2.187
USD
|
+1.26%
|
|
+12.17%
|
-68.84%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
318.3
|
225
|
38
|
16.6
|
6.692
|
-
|
-
|
Enterprise Value (EV)
1 |
318.3
|
225
|
38
|
16.6
|
6.692
|
6.692
|
6.692
|
P/E ratio
|
-15.7
x
|
-7.1
x
|
-0.99
x
|
-0.59
x
|
-0.46
x
|
-0.56
x
|
-0.71
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
2,553
x
|
76.6
x
|
22.6
x
|
15.6
x
|
22.3
x
|
1.16
x
|
EV / Revenue
|
-
|
2,553
x
|
76.6
x
|
22.6
x
|
15.6
x
|
22.3
x
|
1.16
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-18
x
|
-6.87
x
|
-
|
-
|
-0.27
x
|
-0.19
x
|
-0.18
x
|
FCF Yield
|
-5.57%
|
-14.6%
|
-
|
-
|
-374%
|
-528%
|
-558%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
889
|
1,015
|
1,448
|
2,365
|
3,098
|
-
|
-
|
Reference price
2 |
358.0
|
221.8
|
26.25
|
7.020
|
2.160
|
2.160
|
2.160
|
Announcement Date
|
3/10/21
|
3/24/22
|
3/31/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
0.0882
|
0.4958
|
0.7339
|
0.428
|
0.3
|
5.764
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-18.69
|
-31.79
|
-31.8
|
-21.89
|
-26.01
|
-33.97
|
-31.92
|
Operating Margin
|
-
|
-36,055.65%
|
-6,413.1%
|
-2,983.45%
|
-6,077.22%
|
-11,321.83%
|
-553.78%
|
Earnings before Tax (EBT)
1 |
-18.57
|
-31.04
|
-31.77
|
-21.24
|
-25.94
|
-33.88
|
-31.79
|
Net income
1 |
-18.57
|
-31.04
|
-31.77
|
-21.24
|
-25.97
|
-33.88
|
-31.79
|
Net margin
|
-
|
-35,207.25%
|
-6,407.71%
|
-2,894.69%
|
-6,067.17%
|
-11,293.17%
|
-551.54%
|
EPS
2 |
-22.75
|
-31.25
|
-26.50
|
-11.85
|
-4.700
|
-3.890
|
-3.030
|
Free Cash Flow
1 |
-17.72
|
-32.75
|
-
|
-
|
-25
|
-35.3
|
-37.35
|
FCF margin
|
-
|
-37,145.04%
|
-
|
-
|
-5,841.82%
|
-11,768%
|
-648.03%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/10/21
|
3/24/22
|
3/31/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
0.012
|
0.0674
|
0.028
|
0.0876
|
0.3128
|
0.0514
|
0.3334
|
0.2348
|
0.1143
|
0.2033
|
0.075
|
0.075
|
0.075
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-10.1
|
-8.44
|
-8.773
|
-7.281
|
-7.381
|
-7.086
|
-5.019
|
-4.421
|
-5.369
|
-5.791
|
-6.148
|
-6.492
|
-7.58
|
-8.471
|
-8.637
|
Operating Margin
|
-84,136.67%
|
-12,515.36%
|
-31,331.46%
|
-8,312.16%
|
-2,359.74%
|
-13,778.83%
|
-1,505.6%
|
-1,883.03%
|
-4,695.8%
|
-2,848.87%
|
-8,197.33%
|
-8,655.33%
|
-10,106.67%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-10.05
|
-8.376
|
-8.746
|
-7.274
|
-7.373
|
-7.051
|
-5.02
|
-4.409
|
-4.762
|
-5.735
|
-6.143
|
-6.486
|
-7.575
|
-8.471
|
-8.637
|
Net income
1 |
-10.05
|
-8.376
|
-8.746
|
-7.274
|
-7.373
|
-7.051
|
-5.02
|
-4.409
|
-4.762
|
-5.735
|
-6.143
|
-6.486
|
-7.575
|
-8.471
|
-8.637
|
Net margin
|
-83,748.08%
|
-12,419.93%
|
-31,236.89%
|
-8,305.17%
|
-2,357.32%
|
-13,710.62%
|
-1,505.99%
|
-1,878.19%
|
-4,165.49%
|
-2,821.44%
|
-8,190.67%
|
-8,648.67%
|
-10,100%
|
-
|
-
|
EPS
2 |
-10.00
|
-8.750
|
-8.500
|
-7.250
|
-2.500
|
-4.750
|
-3.500
|
-2.250
|
-11.44
|
-2.400
|
-1.780
|
-0.9500
|
-0.9400
|
-0.4300
|
-0.3300
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/24/22
|
5/11/22
|
8/11/22
|
11/14/22
|
3/31/23
|
5/11/23
|
8/14/23
|
11/14/23
|
3/28/24
|
5/14/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-17.7
|
-32.7
|
-
|
-
|
-25
|
-35.3
|
-37.3
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
1.1
|
0.87
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
985.15%
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/10/21
|
3/24/22
|
3/31/23
|
3/28/24
|
-
|
-
|
-
|
Last Close Price
2.16
USD Average target price
17
USD Spread / Average Target +687.04% Consensus |
1st Jan change
|
Capi.
|
---|
| -68.84% | 6.69M | | +33.11% | 50.85B | | +1.00% | 42.82B | | +49.34% | 42.03B | | -4.96% | 29.55B | | +11.01% | 26.11B | | -21.63% | 19.13B | | +9.18% | 13.05B | | +27.64% | 12.16B | | +24.08% | 12.08B |
Other Biotechnology & Medical Research
|